ArticleDiagnostics (Basel, Switzerland)2025
Desmosine: The Rationale for Its Use as a Biomarker of Therapeutic Efficacy in the Treatment of Pulmonary Emphysema.
Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Desmosine in Aortic Disease: Biology, Measurement, and Clinical Applications in Aortic Pathologies.Journal of clinical medicine · 2026Review
- Percolation Forces in Lung Inflammation: Determining the Path to Emphysema or Fibrosis.Biomedicines · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desmosine and isodesmosine (DID) are elastin-specific crosslinking amino acids that play a critical role in maintaining the structural integrity of elastic fibers, and their levels in body fluids may serve as biomarkers for alveolar wall injury. To support this concept, we present studies demonstrating the use of DID to detect elastic fiber damage that reflects distention and the rupture of airspaces. The emergence of airspace enlargement may be modeled by a percolation network describing the effect of changing proportions of intact and weak elastic fibers on the transmission of mechanical forces in the lung. Following the unraveling and fragmentation of weakened elastic fibers, the release of DID may correlate with an increasing alveolar diameter and provide an endpoint for clinical trials of novel agents designed to treat pulmonary emphysema. The limitations of the DID measurements related to specificity and reproducibility are also addressed, particularly regarding sample source and analytical techniques. Standardizing protocols to isolate and quantify DID may increase the use of this biomarker for the early detection of alveolar wall injury, which permits timely therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.